Showing results (231-240 of 259) with videos related to
Sort By:
Pageof 26
Annals of the New York Academy of Sciences|April 6, 2023
Progress in vaccine development for infectious diseases-a Keystone Symposia reportJennifer Cable, Barney S Graham, Richard A Koup, et al.Biorxiv : the Preprint Server for Biology|March 24, 2021
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccinesAlexandra C Walls, Marcos C Miranda, Minh N Pham, et al.Cell|February 12, 2022
Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccinationKatharina Röltgen, Sandra C A Nielsen, Oscar Silva, et al.The Journal of Clinical Investigation|May 1, 2024
Integrated longitudinal multiomics study identifies immune programs associated with acute COVID-19 severity and mortalityJeremy P Gygi, Cole Maguire, Ravi K Patel, et al.The Journal of Experimental Medicine|February 5, 2021
Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccinePaul Bastard, Eleftherios Michailidis, Hans-Heinrich Hoffmann, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 30, 2025
Evaluating COVID-19 severity prediction and immune dynamics with NULISAseq: Insights from the IMPACC studyKoji Abe, Tyson H Holmes, Tran T Nguyen, et al.Biorxiv : the Preprint Server for Biology|November 21, 2023
Integrated longitudinal multi-omics study identifies immune programs associated with COVID-19 severity and mortality in 1152 hospitalized participantsJeremy P Gygi, Cole Maguire, Ravi K Patel, et al.Science Translational Medicine|August 17, 2022
Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccinePrabhu S Arunachalam, Yupeng Feng, Usama Ashraf, et al.Ebiomedicine|August 11, 2022
Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC studyAl Ozonoff, Joanna Schaenman, Naresh Doni Jayavelu, et al.Research Square|June 30, 2025
Empiric Azithromycin in COVID-19 Impacts the Respiratory Microbiome and Antimicrobial Resistome without Anti-inflammatory BenefitCharles Langelier, Abigail Glascock, Cole Maguire, et al.Pageof 26